We are delighted to announce that our seminal paper A novel process driving Alzheimer’s validated in a mouse model: therapeutic potential’ has been accepted by the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. At last, our disruptive approach to Alzheimer’s, proof of concept of our basic hypothesis, and efficacy of our novel drug NBP14, will have a wider public platform. We see this MS as a real milestone since it brings together previously disparate reports in the literature for mapping the steps in the neurodegenerative process and suggests a first-in-class drug treatment, now acknowledged by the MHRA as completely innovative. Although the manuscript is under embargo for 6 weeks, we are currently planning a press conference in early April. More details will be available as plans become clearer, but please watch this space!
LATEST NEWS
- Neuro-Bio new publication – A novel 14mer peptide, T14, is associated with age-dependent behaviour in female mice
- Baroness Greenfield attends Club Vita Webinar “The Risk of Living Longer S02 E04: Preventing Dementia”
- Baroness Greenfield’s Interview at La Vanguardia – A Spanish Newspaper, based in Barcelona talking about Alzheimer’s Disease
- Baroness Greenfield’s Presentation at Brain Innovation Days in Brussels – November 2024!
- Neuro-Bio new publication – A Novel 14mer Peptide Inhibits Autophagic Flux via Selective Activation of the mTORC1 Signalling Pathway: Implications for Alzheimer’s Disease